concept

SRPK1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SRPK1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

296Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

4Experiments

2Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	SRPK1
Key Genes/Proteins	ABCG2, Actin, AKT, ALZHEIMER, ALZHEIMER'S DISEASE, AND
Related Diseases	Als, ALS, Alzheimer
Related Pathways	alternative splicing, Angiogenesis, apoptosis, Apoptosis

Pathway Diagram

graph TD
    SRPK1["SRPK1"]
    SRPK1 -->|"phosphorylates"| PROTAMINE["PROTAMINE"]
    SRPK1 -->|"involved_in"| GENOME_REPROGRAMMING["GENOME REPROGRAMMING"]
    SRPK1 -->|"catalyzes"| Parental_Genome_Reprogramming["Parental Genome Reprogramming"]
    SRPK1 -->|"expressed in"| Fertilized_Oocyte["Fertilized Oocyte"]
    SRPK1 -->|"target for"| Hepatitis["Hepatitis"]
    SRPK1 -->|"activates"| Ms["Ms"]
    SRPK1 -->|"phosphorylates"| ALS["ALS"]
    SRPK1 -->|"target for"| Apoptosis["Apoptosis"]
    h_dca3e907["h-dca3e907"] -->|"targets"| SRPK1
    GENES["GENES"] -->|"inhibits"| SRPK1
    DNA["DNA"] -->|"activates"| SRPK1
    TAF15["TAF15"] -->|"inhibits"| SRPK1
    Plexin_B1["Plexin-B1"] -->|"regulates"| SRPK1
    U2AF1_Protein["U2AF1 Protein"] -->|"references"| SRPK1

Outgoing (159)

Target	Relation	Type	Str
Protamine-to-histone exchange	associated_with	process	0.95
PROTAMINE	phosphorylates	entity	0.95
GENOME REPROGRAMMING	involved_in	entity	0.92
VEGF	upregulates	protein	0.85
Splicing Kinase	expressed_in	enzyme	0.82
apoptosis pathway	participates_in	pathway	0.80
SR_protein_phosphorylation	mediates	pathway	0.80
Fertilized Oocyte	expressed_in	cell_type	0.75
glioblastoma	regulates	disease	0.70
glioblastoma	phosphorylates	disease	0.70
PI3K-AKT-mTOR signaling	participates_in	pathway	0.70
glioblastoma	associated_with	disease	0.70
VEGF	regulates	gene	0.70
VEGF	inhibits	gene	0.70
Als	phosphorylates	disease	0.65
Cancer	inhibits	disease	0.65
Als	inhibits	disease	0.65
Cancer	expressed_in	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
Neuroinflammation	activates	disease	0.65
Als	expressed_in	disease	0.65
Hepatitis	associated_with	disease	0.65
Hepatitis	therapeutic_target	disease	0.65
Inflammation	activates	disease	0.65
ALS	phosphorylates	disease	0.65
ALS	inhibits	disease	0.65
Ms	activates	disease	0.65
Tumor	inhibits	disease	0.65
Alzheimer	regulates	disease	0.65
Als	associated_with	disease	0.65
Tumor	regulates	disease	0.65
ALS	expressed_in	disease	0.65
CANCER	expressed_in	gene	0.60
APOPTOSIS	phosphorylates	gene	0.60
Angiogenesis	regulates	pathway	0.60
LNCRNA	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
HIF	activates	gene	0.60
APOPTOSIS	inhibits	gene	0.60
Angiogenesis	inhibits	pathway	0.60
ALZHEIMER'S DISEASE	regulates	gene	0.60
ALZHEIMER	associated_with	disease	0.60
SRSF1	regulates	gene	0.60
SRSF1	activates	gene	0.60
SRSF1	expressed_in	gene	0.60
SRSF1	inhibits	gene	0.60
cancer	inhibits	disease	0.60
WFS1	interacts_with	gene	0.60
WFS1	associated_with	gene	0.60
CANCER	associated_with	disease	0.60

Incoming (137)

Source	Relation	Type	Str
h-dca3e907	targets	hypothesis	0.90
HLA	associated_with	gene	0.60
ERBB3	targets	gene	0.60
HNRNPA2B1	inhibits	gene	0.60
HNRPU	inhibits	gene	0.60
PI3K	regulates	gene	0.60
NEAT1	activates	gene	0.60
MMP2	inhibits	gene	0.60
MMP9	inhibits	gene	0.60
VEGF	activates	gene	0.60
NUCLEOLIN	inhibits	gene	0.60
RHOA	regulates	gene	0.60
AKT	regulates	gene	0.60
AKT	activates	gene	0.60
BAX	activates	gene	0.60
EGFR	associated_with	gene	0.60
EGFR	expressed_in	gene	0.60
EGFR	interacts_with	gene	0.60
AKT	associated_with	gene	0.60
LEF1	activates	gene	0.60
GENES	inhibits	gene	0.60
ABCG2	interacts_with	gene	0.60
DNA	regulates	gene	0.60
HNRNPA2B1	regulates	gene	0.60
PI3K	phosphorylates	gene	0.60
MMP2	regulates	gene	0.60
MMP9	regulates	gene	0.60
MMP2	expressed_in	gene	0.60
MMP9	expressed_in	gene	0.60
ASTROCYTES	regulates	gene	0.60
EGFR	activates	gene	0.60
angiogenesis	phosphorylates	process	0.60
RNA	inhibits	gene	0.60
AND	inhibits	gene	0.60
AND	phosphorylates	gene	0.60
APOPTOSIS	activates	gene	0.60
DNA	interacts_with	gene	0.60
RNA	interacts_with	gene	0.60
APOPTOSIS	phosphorylates	gene	0.60
LNCRNA	activates	gene	0.60
ROS	activates	gene	0.60
APOPTOSIS	inhibits	gene	0.60
ALZHEIMER	therapeutic_target	gene	0.60
DRAK2	inhibits	gene	0.60
DNA	activates	gene	0.60
PI3K	associated_with	gene	0.60
ATP	inhibits	gene	0.60
GENES	regulates	gene	0.60
AND	regulates	gene	0.60
RNA	expressed_in	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Serine/Arginine-Rich Protein Kinase Modulation	0.624	neurodegeneration	TDP-43 phase separation therapeutics for

Mentioning Analyses (1)

Scientific analyses that reference this entity

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.738

Experiments (4)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Proposed experiment from debate on Microglia activate astrocytes via I	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
s:** - Temporal analysis showing mitochondrial defects precede other p	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
ALS Progression Rate Heterogeneity — mechanism and biomarker predictor	clinical	ALS	0.400	0.50	human	proposed	$6,550,000
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Development	validation	Neurodegeneration	0.400	0.50	human	proposed	$2,280,000

Related Papers (16)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-asso [PMID:34614409]	Li Y, Xu J, Lu Y, Bian H, Yang L, Wu H,	Cell Metab	2021	1
Initiation of Parental Genome Reprogramming in Fertilized Oocyte by Splicing Kin [PMID:32169215]	Gou LT, Lim DH, Ma W, Aubol BE, Hao Y, W	Cell	2020	1
ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fert [PMID:23177736]	Zheng G, Dahl JA, Niu Y, Fedorcsak P, Hu	Mol Cell	2013	1
Palmitoylation-Mediated Ubiquitination of SRPK1 Regulates Ferroptosis in High-Fa [PMID:41610308]	Tan XH, Li KF, Yuan YM, Xia MC, Zhao FZ	Adv Sci (Weinh)	2026	0
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combin [PMID:40272619]	["Shim S", "Reinacher-Schick A", "Kraeft	Investigational new drugs	2025	0
Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF spl [PMID:41133227]	["Treppiedi D", "Di Bari S", "Mangili F"	Frontiers in endocrinology	2025	0
Proteome and Phosphoproteome Profiling Reveal the Toxic Mechanism of [PMID:39330852]	["Yue N", "Huang J", "Dong M", "Li J", "	Toxins	2024	0
Integration of multi-omics transcriptome-wide analysis for the identification of [PMID:39719581]	["Yi G", "Li Z", "Sun Y", "Ma X", "Wang	Journal of translational medic	2024	0
Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhanci [PMID:36869126]	["Huang J", "Duan L", "Liu Q", "Li H", "	Oncogene	2023	0
SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alter [PMID:33602301]	["Liu H", "Gong Z", "Li K", "Zhang Q", "	Journal of experimental & clin	2021	0
SRPK1 is a poor prognostic indicator and a novel potential therapeutic target fo [PMID:30214242]	["Yi N", "Xiao M", "Jiang F", "Liu Z", "	OncoTargets and therapy	2018	0
Quantitative Temporal Viromics of an Inducible HIV-1 Model Yields Insight to Glo [PMID:28606917]	["Lapek J", "Lewinski M", "Wozniak J", "	Molecular & cellular proteomic	2017	0
RNA splicing and splicing regulator changes in prostate cancer pathology. [PMID:28382513]	["Munkley J", "Livermore K", "Rajan P",	Human genetics	2017	0
Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and v [PMID:28341661]	Ved N, Hulse RP, Bestall SM, Donaldson L	Clinical science (London, Engl	2017	0
MiR-9 regulates the post-transcriptional level of VEGF165a by targeting SRPK-1 i [PMID:25007957]	["Yoon C", "Kim D", "Kim S", "Park G", "	Graefe's archive for clinical	2014	0
SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment fo [PMID:22817743]	["Oltean S", "Gammons M", "Hulse R", "Ha	Biochemical Society transactio	2012	0

Debates (2)

Multi-agent debates referencing this entity

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

TDP-43 phase separation therapeutics for ALS-FTD

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

Related Research

Hypotheses and analyses mentioning SRPK1 in their description or question text

No additional research found